•
Mar 31, 2022
ResMed Q3 2022 Earnings Report
ResMed's Q3 2022 results reflected strong performance with double-digit top-line revenue growth and solid high-single-digit growth in software-as-a-service.
Key Takeaways
ResMed Inc. reported a 12% increase in revenue to $864.5 million for the quarter ended March 31, 2022. Diluted earnings per share were $1.22, and non-GAAP diluted earnings per share were $1.32.
Revenue increased by 12% to $864.5 million, or 14% on a constant currency basis.
Gross margin contracted 140 bps to 56.8%, while non-GAAP gross margin contracted 150 bps to 58.1%.
Income from operations increased 5%, with non-GAAP operating profit also up 5%.
Diluted earnings per share were $1.22, and non-GAAP diluted earnings per share were $1.32.
ResMed
ResMed
ResMed Revenue by Segment
ResMed Revenue by Geographic Location
Forward Guidance
The company did not provide specific forward guidance in this earnings report.